Cargando…

Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition

During the past decade there has been renewed interest in the use of vaccine immunotherapy for the treatment of cancer. This review focuses on HER2/neu, a tumour-associated antigen that is overexpressed in 10–40% of breast cancers and other carcinomata. Several immunogenic HER2/neu peptides recogniz...

Descripción completa

Detalles Bibliográficos
Autores principales: Correa, Isabel, Plunkett, Tim
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138708/
https://www.ncbi.nlm.nih.gov/pubmed/11737893
http://dx.doi.org/10.1186/bcr330
_version_ 1782120479136415744
author Correa, Isabel
Plunkett, Tim
author_facet Correa, Isabel
Plunkett, Tim
author_sort Correa, Isabel
collection PubMed
description During the past decade there has been renewed interest in the use of vaccine immunotherapy for the treatment of cancer. This review focuses on HER2/neu, a tumour-associated antigen that is overexpressed in 10–40% of breast cancers and other carcinomata. Several immunogenic HER2/neu peptides recognized by T lymphocytes have been identified to be included in cancer vaccines. Some of these peptides have been assessed in clinical trials of patients with breast and ovarian cancer. Although it has been possible to detect immunological responses against the peptides in the immunized patients, no clinical responses have so far been described. Immunological tolerance to self-antigens like HER2/neu may limit the functional immune responses against them. It will be of interest to determine whether immune responses against HER2/neu epitopes can be of relevance to cancer treatment.
format Text
id pubmed-138708
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1387082003-02-27 Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition Correa, Isabel Plunkett, Tim Breast Cancer Res Review During the past decade there has been renewed interest in the use of vaccine immunotherapy for the treatment of cancer. This review focuses on HER2/neu, a tumour-associated antigen that is overexpressed in 10–40% of breast cancers and other carcinomata. Several immunogenic HER2/neu peptides recognized by T lymphocytes have been identified to be included in cancer vaccines. Some of these peptides have been assessed in clinical trials of patients with breast and ovarian cancer. Although it has been possible to detect immunological responses against the peptides in the immunized patients, no clinical responses have so far been described. Immunological tolerance to self-antigens like HER2/neu may limit the functional immune responses against them. It will be of interest to determine whether immune responses against HER2/neu epitopes can be of relevance to cancer treatment. BioMed Central 2001 2001-09-20 /pmc/articles/PMC138708/ /pubmed/11737893 http://dx.doi.org/10.1186/bcr330 Text en Copyright © 2001 BioMed Central Ltd
spellingShingle Review
Correa, Isabel
Plunkett, Tim
Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
title Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
title_full Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
title_fullStr Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
title_full_unstemmed Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
title_short Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
title_sort update on her-2 as a target for cancer therapy: her2/neu peptides as tumour vaccines for t cell recognition
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138708/
https://www.ncbi.nlm.nih.gov/pubmed/11737893
http://dx.doi.org/10.1186/bcr330
work_keys_str_mv AT correaisabel updateonher2asatargetforcancertherapyher2neupeptidesastumourvaccinesfortcellrecognition
AT plunketttim updateonher2asatargetforcancertherapyher2neupeptidesastumourvaccinesfortcellrecognition